Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
26,013.66
(
0.55%
)
Dow Jones
49,447.43
(
0.00%
)
Brent Oil
91.77
(
1.20%
)
Bitcoin
76,500.00
(
0.80%
)
News Focus
News Focus
Post# of 257431
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 74705

Wednesday, 03/18/2009 11:19:31 AM

Wednesday, March 18, 2009 11:19:31 AM

Post# of 257431

MRX needs Reloxin approval and launch (successfully) more than ever.

Approval per se is not seriously in doubt (although the FDA might find a way to delay it for a while) because Reloxin is just another name for Dysport, which has been sold all over the world for decades.

Commercial uptake is another matter. Reloxin is technically inferior to Botox and hence MRX’s best chance is to compete aggressively on price.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today